

February 17, 2026

Hiring Manager

Indegene

Re: Director, Medical Analytics

I am writing to express my interest in the Director, Medical Analytics role at Indegene. With over a decade of analytics leadership in pharmaceutical organizations - including a director-level role embedded within Medical Affairs at Gilead Sciences - I am drawn to Indegene's mission of enabling healthcare organizations to operate at the leading edge of data and technology.

At Gilead Sciences, I led the Insights, Data & Analytics function within Medical Affairs, where I built the enterprise HCP/HCO data infrastructure, defined measurement frameworks for field medical programs, and managed a team of analysts and dashboard developers delivering insights to Medical Affairs leadership. This experience gave me direct exposure to the strategic and operational demands of Medical Affairs analytics - including cross-functional alignment with Regulatory, Market Access, and Medical stakeholders, and the challenge of translating complex engagement data into actionable intelligence.

Beyond Gilead, my background spans director and senior director roles across Takeda and Redica Systems, where I have built production ML systems, designed regulatory intelligence platforms, and presented analytical insights at industry conferences including CHPA and ISPE. My PhD in Mathematics and postdoctoral research in biological systems modeling also provide a strong scientific foundation for working across therapeutic area data and evidence generation contexts.

I am particularly excited about Indegene's model of bringing analytics capabilities to multiple healthcare clients at scale. The opportunity to apply Medical Affairs analytics expertise across a portfolio of therapeutic areas and organizational contexts aligns well with both my background and my interest in high-impact, client-facing analytical leadership.

I would welcome the opportunity to discuss how my experience in pharmaceutical analytics and Medical Affairs data strategy could contribute to Indegene's continued growth. Thank you for your consideration.

Sincerely,

Matt Oremland, PhD